Clinical trial • Not applicable • Musculoskeletal|Neurology

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Postmastectomy pain syndrome

Not applicable trial of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Postmastectomy pain syndrome.

Overview

Trial Therapeutic Area
Musculoskeletal|Neurology
Trial Disease
Postmastectomy pain syndrome
Trial Stage
Not applicable
Drug Modality
Peptide/protein/enzyme|Small molecule

Key dates

Initial CTIS Submission Date
26-06-2024
First CTIS Authorization Date
04-09-2024

Trial design

Randomised, xeomin (incobotulinumtoxina / clostridium botulinum neurotoxin type a) 100 u, intramuscular injection; qutenza (capsaicin) 179 mg cutaneous patch (transdermal).-controlled Not applicable trial across 1 site in Spain.

Randomised
Yes
Comparator
XEOMIN (incobotulinumtoxinA / Clostridium botulinum neurotoxin type A) 100 U, intramuscular injection; Qutenza (capsaicin) 179 mg cutaneous patch (transdermal).
Target Sample Size
30

Eligibility

Recruits 30 No vulnerable populations selected; only adult women (>18 years). Signed informed consent is required from participants; subject information and informed consent form available..

Vulnerable Population
No vulnerable populations selected; only adult women (>18 years). Signed informed consent is required from participants; subject information and informed consent form available.

Inclusion criteria

  • {"criterion_text":"- Women over 18 years of age operated on for unilateral breast neoplasia\n- Patients with painful symptoms defining postmastectomy syndrome.\n- Patients with moderate-severe pain.\n- Signed informed consent form."}

Exclusion criteria

  • {"criterion_text":"- Age less than 18 years\n- Presence of cognitive-behavioral deficits.\n- Patients with bilateral tumor involvement, cases of tumor recurrence, patients referred for non-oncologic breast surgery.\n- Non-acceptance to participate in the study.\n- Breast tumors in men."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Pain assessment: Recording of pain intensity using a visual analogue scale (VAS)","definition_or_measurement_approach":"Recording of pain intensity using a visual analogue scale (VAS)."}
  • {"endpoint_text":"- Characterization of the predominant pain perception: burning, stabbing pain, sensation of pressure or numbness.","definition_or_measurement_approach":"Characterisation of the predominant pain perception as burning, stabbing pain, sensation of pressure or numbness (as recorded in study assessments)."}

Secondary endpoints

  • {"endpoint_text":"- Recording of side effects","definition_or_measurement_approach":"Recording and reporting of adverse events/side effects."}
  • {"endpoint_text":"- Recording of the degree of patient satisfaction","definition_or_measurement_approach":"Recording of patient satisfaction (degree) as per study assessments."}
  • {"endpoint_text":"- Recording of concomitant analgesic medications","definition_or_measurement_approach":"Recording of concomitant analgesic medication use."}

Recruitment

Planned Sample Size
30
Recruitment Window Months
15
Consent Approach
Signed informed consent form required from participants (adult women). Subject information and informed consent form available (document L1). Study materials and translations include Spanish.

Geography

Total Number Of Sites
1
Total Number Of Participants
30

Spain

Earliest CTIS Part Ii Submission Date
02-08-2024
Latest Decision Or Authorization Date
04-09-2024
Processing Time Days
33
Number Of Sites
1
Number Of Participants
30

Sites

Site Name
Hospital Universitario Dr Peset Aleixandre
Department Name
physical medicine and rehabilitation
Principal Investigator Name
Maria Rosario Beseler Soto
Principal Investigator Email
beseler_ros@gva.es
Contact Person Name
Maria Rosario Beseler Soto
Contact Person Email
beseler_ros@gva.es
Number Of Participants
30

Sponsor

Primary sponsor

Full Name
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Organisation Type
Patient organisation/association
Country Of Registered Address
Spain

Third parties

  • {"country":"","full_name":"Merz Therapeutics","duties_or_roles":"Monetary support","organisation_type":""}
  • {"country":"","full_name":"Hospital Universitario Doctor Peset","duties_or_roles":"Monetary support","organisation_type":""}

Investigational products

Investigational Product Name
XEOMIN 100 unidades polvo para solución inyectable
Active Substance
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
Modality
Peptide/protein/enzyme
Routes Of Administration
Intramuscular
Route
Intramuscular
Authorisation Status
Authorised (marketing authorisation number 69292)
Maximum Dose
100 U
Investigational Product Name
Qutenza 179 mg cutaneous patch
Active Substance
CAPSAICIN
Modality
Small molecule
Routes Of Administration
Transdermal
Route
Transdermal
Authorisation Status
Authorised (marketing authorisation EU/1/09/524/001)
Maximum Dose
179 mg

Related trials

Other published trials that may interest you.